This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Extended Pleurectomy Decortication and Chemotherapy Versus Chemotherapy Alone for Pleural Mesothelioma (MARS 2): A Phase 3 Randomized Controlled Trial

Thursday, June 20, 2024

Submitted by


Source Name: The Lancet Respiratory Medicine


Eric Lim, David Waller, Kelvin Lau, Jeremy Steele, Anthony Pope, Clinton Ali, Rocco Bilancia, Manjusha Keni, Sanjay Popat, Mary O'Brien, Nadza Tokaca, Nick Maskell, Louise Stadon, Dean Fennell, Louise Nelson, John Edwards, Sara Tenconi, Laura Socci, Robert C Rintoul, Kelly Wood, Amanda Stone, Dakshinamoorthy Muthukumar, Charlotte Ingle, Paul Taylor, Laura Cove-Smith, Raffaele Califano, Yvonne Summers, Zacharias Tasigiannopoulos, Andrea Bille, Riyaz Shah , Elizabeth Fuller, Andrew Macnair, Jonathan Shamash, Talal Mansy, Richard Milton, Pek Koh, Andreea Alina Ionescu, Sarah Treece, Amy Roy, Prof Gary Middleton, Alan Kirk, Rosie A Harris, Kate Ashton, Barbara Warnes, Emma Bridgeman, Katherine Joyce, Nicola Mills, Daisy Elliott, Nicola Farrar, Elizabeth Stokes, Vikki Hughes, Andrew G Nicholson, Chris A Rogers

In this phase three national, multicenter, UK randomized controlled trial, the authors seek to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. The trial recruited patients between 2015 and 2021 from 26 UK hospitals, recruiting and randomly assigning patients with a 1:1 allocation ratio. In total 335 patients were randomized, 87 percent of which were male. The authors concluded that extended pleurectomy decortication was associated with a worse survival up to two years.

Add comment

Log in or register to post comments